Rockefeller Capital Management
PHAT icon

Rockefeller Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Rockefeller Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.5K Buy
4,095
+3,940
+2,542% +$49.8K ﹤0.01% 3330
2025
Q4 		$2.57K Buy
+155
New +$2.21K ﹤0.01% 4259
2023
Q1 		– Sell
-29
Closed – – 3360
2022
Q4 		$0 Hold
29
– – ﹤0.01% 4128
2022
Q3 		$0 Hold
29
– – ﹤0.01% 4268
2022
Q2 		$0 Buy
+29
New +$298 ﹤0.01% 4329
2020
Q3 		– Sell
-17,388
Closed -$572K – 2739
2020
Q2 		$572K Buy
+17,388
New +$668K 0.01% 664

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Rockefeller Capital Management's PHAT Position: Q1 2026 in Review

Rockefeller Capital Management increased its Phathom Pharmaceuticals (PHAT) stake by 2,542% in Q1 2026, buying an estimated $49.8K and bringing the position to 4,095 shares worth $45.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3330.

Rockefeller Capital Management first reported a position in PHAT in Q2 2020 and has held it in 6 quarters since. The position peaked at $572K in Q2 2020. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Rockefeller Capital Management held 4,095 shares of Phathom Pharmaceuticals worth $45.5K as of Q1 2026.
  • Rockefeller Capital Management bought 3,940 Phathom Pharmaceuticals shares in Q1 2026, an estimated $49.8K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3330 holding.
  • Rockefeller Capital Management first reported a position in Phathom Pharmaceuticals in Q2 2020 and has held it in 6 quarters since.
  • Rockefeller Capital Management's Phathom Pharmaceuticals position peaked at $572K in Q2 2020.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.